| Name | Title | Contact Details |
|---|
GYMGUYZ® is proud to be the FIRST in Home Mobile Personal Training and Fitness Franchise Company. As #1 in Home Personal Training, we offer individualized one-on-one workouts, group instruction and corporate fitness. GYMGUYZ® has an amazing team of certified coaches that incorporate the GYMGUYZ® philosophy of the 3 C`s during each workout. Our workouts are Convenient, Customized & Creative. For your convenience, we travel to you in our GYMGUYZ® van to your home, office, park or setting of your choice, at a time that works best for you. Each van is stocked with state of the art fitness equipment enabling the GYMGUYZ® coach to provide you with your customized workout. Our certified coaches are trained using the GYMGUYZ® methodologies. We utilize the tools and techniques required for a creative exercise program with high quality service. No two workouts are ever the same!
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
OtisMed Corporation is a Alameda, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The mission of the Society is to enhance the ability of cardiothoracic surgeons to provide the highest quality patient care through education, research, and advocacy. Learn more at www.sts.org.
Digital Healthcare is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.